Ageing & Longevity

The optimal model system for early insights into ageing research

Advancing ageing research – C. elegans significance

The global impact of ageing and age-related disease on our society is increasing as life expectancy rises. C. elegans has played a fundamental role in advancing ageing research and exhibits many relevant ageing hallmarks, together with useful study attributes (short lifecycle and lifespan, large test populations and human gene homology)

We provide you with an optimal model system to test if your compound or product slows ageing, with key insights into its target and mode of action.

Conversely, if you have a drug you know has an impact on slowing ageing, but don’t understand how it works to do this, it’s very challenging to design a study to determine this mode of action and understand the target ID.

Our advantage for ageing and longevity studies:

Consultancy from leading experts in ageing and longevity for study design input
Automated WormGazer^TM technology with high throughput and data reproducibility
Target identification and transgenic approaches to understand mechanisms of action
Multi-faceted healthspan approach, with rich customisable data on health, ageing and longevity
Large populations allow the heterogeneity of ageing to be studied consistently and with time efficient experiments

Enrich data for rapid research progress

In vitro assays in primary cell lines, explants and organoids are very limited models for senescence and ageing research due to the huge variability in the biological age of cells, and a lack of interaction with other organs and physiological systems.

Mammalian models of ageing are more representative, but they involve long timelines, are costly and have complex regulatory requirements. Our ageing and longevity studies in C.elegans can significantly enrich and compliment data from other models and in vitro experiments. In addition, they can de-risk the transition of your compounds from in vitro studies to mouse studies, by testing them in a whole organism earlier, without regulatory requirements.

“Our project with Magnitude Biosciences showed the power of this unique C. elegans healthspan approach over lifespan as it enables you to measure ageing in mid-life, not just recording when animals die. I would strongly recommend their healthspan assays to other biotechs and pharma looking to develop treatments for age-related disease..”

William Bains, CSO, Five Alarm Bio.

Case Study: Measuring efficacy to slow ageing for drug discovery biotech Five Alarm Bio

Five Alarm Bio, a UK drug discovery startup focussing on the underlying mechanisms of ageing to develop therapeutics for age-related disease, works with Magnitude Biosciences to test their compound, FAB001, to test their hypothesis on the nature of ageing.